Please ensure Javascript is enabled for purposes of website accessibility
Inicio > Productos > Anticuerpos > Biosimilares

Anti-Human CTLA-4 Reference Antibody (Tremelimumab, RUO) (HB651036)

Anti-Human CTLA-4 Reference Antibody (Tremelimumab, RUO)
Anti-Human CTLA-4 Reference Antibody (Tremelimumab, RUO)
Anti-Human CTLA-4 Reference Antibody (Tremelimumab, RUO)
Anti-Human CTLA-4 Reference Antibody (Tremelimumab, RUO)
Precio(USD):
Especificación:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Número:
Contáctenos
  • Vista general

  • Imágenes

  • Referencias

  • Datasheet

  • SDS

Vista general
Número de catálogoHB651036
Descripción
Tremelimumab (HB651036) is a research-grade recombinant antibody targeting CD152. Produced in mammalian cells with native-like glycosylation.
Highlights
  • ●Research Grade — For PK/PD studies, assay development, and ADA research.
  • ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especiesHuman
AplicacionesELISA, Bioactivity: FCM, Functional assay, Research in vivo
Especie huéspedHuman
ClonalidadMonoclonal
IsotipoIgG2-kappa
Objetivo CD152, CTLA-4, CTLA4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4
Nivel de endotoxinas < 10 EU/mg
Pureza >95% as determined by SDS-PAGE.
Purificación Protein A/G purified from cell culture supernatant.
Número de acceso P16410
Forma Liquid
Buffer de almacenamiento 0.01M PBS pH 7.4.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Estabilidad y almacenamiento Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativosTicilimumab, CP-675, CP-675, 206, CP-675206clone11.2.1, 745013-59-6
Fondo

Cytotoxic T-lymphocyte protein 4 (CD152/CTLA4) is a ~24 kDa protein. Inhibitory receptor acting as a major negative regulator of T-cell responses. Acts as a decoy receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. CD152 is the therapeutic target of ipilimumab (Yervoy).

1. Schwartz, JC. et al. (2001) Nature 410, 604-8. PMID: 11279501
2. Stamper, CC. et al. (2001) Nature 410, 608-11. PMID: 11279502
3. Teft, WA. et al. (2006) Annual review of immunology 24, 65-97. PMID: 16551244
4. Linsley, PS. et al. (1991) The Journal of experimental medicine 174, 561-9. PMID: 1714933
5. Zheng, Y. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 1683-91. PMID: 18641304
6. Ramagopal, UA. et al. (2017) Proceedings of the National Academy of Sciences of the United States of America 114, E4223-E4232. PMID: 28484017
Nota For research use only. Not suitable for clinical or therapeutic use.
Isotype Control Human IgG2 Recombinant Isotype Control Antibody (HyHEL-10) (HV988107)
Imágenes
  • Anti-Human CTLA-4 Reference Antibody (Tremelimumab, RUO)

    Bioactivity

    Detects Human CD152/CTLA4 in indirect ELISAs.

  • Anti-Human CTLA-4 Reference Antibody (Tremelimumab, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Tremelimumab

Referencias
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: [email protected]

Lista de distribuidores